For research use only. Not for therapeutic Use.
Actinomycin D (Cat.No:I003805) is a potent anti-cancer antibiotic that is commonly used in chemotherapy. It binds to DNA and inhibits RNA transcription, leading to the disruption of cell division and growth. Actinomycin D has been used to treat a variety of cancers, including Wilms’ tumor, testicular cancer, and gestational trophoblastic neoplasia. It is also being studied for its potential use in gene therapy.
| Catalog Number | I003805 |
| CAS Number | 50-76-0 |
| Synonyms | 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| Molecular Formula | C62H86N12O16 |
| Purity | ≥95% |
| Target | Apoptosis Inducers |
| Solubility | DMSO: ≤ 250 mg/mL (Need ultrasonic), Methanol: ≤ 20 mg/mL (Need ultrasonic), H2O: ＜ 12.5 mg/mL, Methanol: ≤ 6.2 mg/mL |
| Storage | Store at 4°C |
| IUPAC Name | 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[(3R,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide |
| InChI | InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1 |
| InChIKey | RJURFGZVJUQBHK-DCUCITLNSA-N |
| SMILES | C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C |
| Reference | </br>1:Pre-clinical drug screen reveals topotecan, actinomycin D and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Schmidt C, Schubert NA, Brabetz S, Mack N, Schwalm B, Chan JA, Selt F, Herold-Mende C, Witt O, Milde T, Pfister SM, Korshunov A, Kool M.Neuro Oncol. 2017 May 8. doi: 10.1093/neuonc/nox093. [Epub ahead of print] PMID: 28482026 </br>2:Actinomycin D synergistically enhances the cytotoxicity of CDDP on KB cells by activating P53 via decreasing P53-MDM2 complex. Wang L, Pang XC, Yu ZR, Yang SQ, Liu AL, Wang JH, Du GH.J Asian Nat Prod Res. 2017 Apr 25:1-14. doi: 10.1080/10286020.2017.1318853. [Epub ahead of print] PMID: 28440085 </br>3:Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells. Das T, Nair RR, Green R, Padhee S, Howell M, Banerjee J, Mohapatra SS, Mohapatra S.Anticancer Res. 2017 Apr;37(4):1655-1663. PMID: 28373426 </br>4:Human p53 interacts with the elongating RNAPII complex and is required for the release of actinomycin D induced transcription blockage. Borsos BN, Huliák I, Majoros H, Ujfaludi Z, Gyenis Á, Pukler P, Boros IM, Pankotai T.Sci Rep. 2017 Jan 19;7:40960. doi: 10.1038/srep40960. PMID: 28102346 Free PMC Article</br>5:Assessment of binding properties of Actinomycin-D to 21nt DNA segment of hmgb1 gene promoter using spectroscopic and calorimetric techniques. Lohani N, Singh HN, Rajeswari MR.J Biomol Struct Dyn. 2017 Feb 8:1-8. doi: 10.1080/07391102.2016.1278037. [Epub ahead of print] No abstract available. PMID: 28033959 </br>6:Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease. Lee YJ, Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH.J Gynecol Oncol. 2017 Mar;28(2):e8. doi: 10.3802/jgo.2017.28.e8. Epub 2016 Oct 7. PMID: 27819410 Free PMC Article</br>7:Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide. Choi A, Kang YK, Lim S, Kim DH, Lim JS, Lee JA.Cancer Res Treat. 2016 Oct;48(4):1443-1447. Epub 2016 Mar 30. PMID: 27034141 Free PMC Article</br>8:Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis. Liu XF, Xiang L, Zhou Q, Carralot JP, Prunotto M, Niederfellner G, Pastan I.Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10666-71. doi: 10.1073/pnas.1611481113. Epub 2016 Sep 6. PMID: 27601652 Free PMC Article</br>9:Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Tzaridis T, Milde T, Pajtler KW, Bender S, Jones DT, Müller S, Wittmann A, Schlotter M, Kulozik AE, Lichter P, Peter Collins V, Witt O, Kool M, Korshunov A, Pfister SM, Witt H.Oncotarget. 2016 Sep 20;7(38):61860-61873. doi: 10.18632/oncotarget.11452. PMID: 27556362 Free PMC Article</br>10:Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia. Lertkhachonsuk AA, Hanvoravongchai P.J Reprod Med. 2016 May-Jun;61(5-6):230-4. PMID: 27424364 |
